Literature DB >> 28109687

[Ocular graft-versus-host disease: An often misdiagnosed etiology of dry eye syndrome].

L Moyal1, R Adam2, J Akesbi2, F T Rodallec2, J-P Nordmann2.   

Abstract

PURPOSE: To report a case of severe ocular graft-versus-host disease (GVHD) after cataract surgery.
METHODS: Observational case report.
RESULTS: We describe the case of a 59-year-old man with postoperative corneal ulcer on his only functional eye. His past history reported allogenic bone marrow transplant. His visual acuity (VA) was limited to hand motions. Slit lamp examination revealed diffuse conjunctival hyperemia, severe blepharitis, Meibomian dysfunction, total corneal opacification with epithelial and stromal keratitis and neovascular invasion. Because of the severe dry eye symptoms and history of allogenic hematological stem cell transplantation, ocular GVHD was diagnosed. Functional and anatomical improvement occurred rapidly with topical cyclosporine 2%, with improved VA after treatment.
CONCLUSION: With any severe dry eye syndrome in the context of allogenic bone marrow transplant, ocular GVHD must be considered. For planned ocular surgery, we recommend adding cyclosporine 0.1% treatment before and after surgery to prevent severe ocular GVHD.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Ciclosporine topique; Dry eye; Ocular graft-versus-host disease; Réaction oculaire du greffon contre l’hôte; Syndrome sec; Topical cyclosporine: Prophyllactic treatment; Traitement préventif

Mesh:

Substances:

Year:  2017        PMID: 28109687     DOI: 10.1016/j.jfo.2016.08.012

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  1 in total

1.  Scleral Lens and Prosthetic Replacement of the Ocular Surface Ecosystem Utilization in Ocular Graft-versus-Host Disease: A Survey Study.

Authors:  Shannon M Bligdon; Bradley A Colarusso; Allen Y Ganjei; Alan Kwok; Zhonghui Katie Luo; Daniel Brocks
Journal:  Clin Ophthalmol       Date:  2021-12-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.